Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?

March 07, 2025 05:14:54 am

Source: SeekingAlpha

2025-03-07 05:14:54 ET

Summary

Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab, but analysts believe the selloff was an overreaction.
Atacicept is more disease-modifying, while sibeprenlimab offers better immediate kidney protection; both have comparable safety profiles.
Sibeprenlimab may hit the market 6 months earlier than atacicept, but complementary actions in IgAN suggest minimal impact on atacicept.
VERA's financials are strong with a cash runway of 10 quarters, but the lack of phase 3 uPCR data remains a key risk.

In February, Vera Therapeutics, Inc. (VERA) stock dropped considerably after Otsuka ( OTSKY ) released earnings, where they disclosed plans to file for an accelerated approval for their rival drug sibeprenlimab for IgA Nephropathy. A number of analysts weighed in on the matter , opining that Otsuka could get to the market "a few months ahead." However, most analysts seemed unconcerned by the disclosure, saying, one, that this was expected, and two, the selloff was an overreaction....